Search

Last updated: Acute Kidney Injury (AKI)
on January 21, 2012

Pneumonia

Key facts:

Authors: Ruth de Souza and Ricky Jones
Top Tips: Rx different types of pneumonia very variable. Use CURB-65

Key Differential Diagnoses

  • Pulmonary embolus
  • Pleural effusion
  • Pneumothorax

Key Investigations

  • O2 saturation (± ABG)
  • ECG, CXR
  • FBC, CRP, U+E, LFT, Bone, Glucose
  • BC, Sputum culture
  • CURB-65 score

Key Treatment

  • OXYGEN, if hypoxic, to achieve SpO2 95-97%
  • PO AMOXICILLN 500 mg tds + PO ERYTHROMYCIN 500 mg qds (non severe CAP only); or other AB regimes
    Note: Do NOT repeat failed regimens given in primary care

Key Management Decision

  • Ventilation

Background

Introduction

  • A CXR is needed to make a diagnosis (see definition). Pneumonia is acute inflammation of the lungs caused by infection. Initial diagnosis is based on the CXR
  • Causes, symptoms, treatment, preventive measures, and prognosis differ markedly; depending on whether the infection is bacterial, viral, fungal, or parasitic; whether it is acquired in the community, hospital, or nursing home; and whether it develops in a patient who is immunocompetent or immunocompromised
  • The aetiological agent cannot be reliably predicted from the clinical picture. Immunocompromised patients can present atypically - eg with SOB (and no CXR signs), or agitation, fever etc
  • Look at the CXR properly, not only to confirm the diagnosis. It should also be used to: (1) delineate the extent of the consolidation; (2) indicate the presence of underlying disorders eg carcinoma; and (3) denote the presence of complications
  • Mortality is 10% in CAP (community-acquired pneumonia); 20% in healthcare–associated pneumonia (HCAP), and hospital-acquired pneumonia (HAP); and 30% in ventilator-associated pneumonia (VAP): [Ref]

Definition

  • LRTI associated with fresh radiological shadowing on CXR

Epidemiology

  • Incidence 1-3/1000 pa

Classification

  • Anatomical: Lobar or Bronchopneumonia
  • Origin: Community-acquired (CAP), Hospital-acquired (HAP), Aspiration or Opportunistic
  • Microbiological

Risk factors

  • Age, alcohol, smoking, HIV/immunosuppression, dementia

Causes

  • Bronchial obstruction, secondary to foreign body or carcinoma
  • Chronic lung disease (Bronchiectasis; asthma/COPD; pulmonary fibrosis, especially cystic fibrosis)
  • Achalasia
  • Co-existing chronic disease (eg failures)
    Note: patients with R sided endocarditis can present with haemoptysis, fever, consolidation ± cavitation

Common organsisms

  • Streptococcus pneumoniae (>30%)
  • Mycoplasma pneumoniae
  • Haemophilus influenzae
  • Viruses (15%)
  • Many other organisms
    NB: 'rare organisms' (eg CMV, PCP and TB) are common in at risk groups (eg HIV and immunosuppressed)

Symptoms

  • Of LRTI
  • Haemoptysis
  • Chest pain, often pleuritic (can be of rapid onset, especially streptococcus pneumoniae)
  • Diarrhoea (legionella)
    NB: in previously normal lungs, most types of pneumonia will not usually (on their own) cause SOB; ie if SOB, think another cause (eg PE); or pneumonia plus something else; or an early opportunistic pneumonia (eg CMV, PCP)

Key questions

  • "When did your symptoms start?"
  • "Do you have any other longterm lung disease, or other chronic diseases?"

Signs

  • Fever, pleural rub (listen over site of maximal pain)
  • Of consolidation
  • Of complication (eg pleural effusion)
  • Of severe sepsis (SOB, tachycardia, drowsiness)

Investigation

Blood

  • FBC (haemolysis think mycoplasma), CRP
  • U+E, LFTs, Bone, Glucose, CK (makes legionella more likely)
    Note: if ARF, think of pulmonary-renal syndrome (dont necessarily have haemoptysis)
  • ABG
    Note: significant hypoxia can lead to minimal changes in vital signs, in fit people
  • Blood culture
  • Serology (for atypical organisms eg legionella, mycoplasma)

Other

  • Urinary dipstick
  • Urine for legionella and pneumococcal antigens
  • Sputum culture, urgent microscopy with gram stain
  • ECG
  • CXR
    Note: need fresh XR changes to make the diagnosis; comparing old and new XRs can be helpful

Lobar pneumonia - Right upper lobe

RUL pneumonia

Right middle lobe pneumonia

Right middle lobe pneumonia

Lobar pneumonia - Right lower lobe

RLL pneumonia (lateral helps to localise)

CXR - bronchopneumonia (usually more serious than lobar)

RLZ bronchopneumonia

CXR - Opportunistic (PCP/PCJ in this case); can be normal initially, all very serious)

        PCP/PCJ pneumonia

Key investigations

  • CXR
  • ABG, if unwell

Specialist investigations

  • Blood:  ZN stain, sputum for AFBs; atypical organisms (mycoplasma pneumoniae,legionella, chlamydia psittaci, influenza A + B)
  • Urine:  Legionella
  • Pleural fluid aspiration/bronchoalveolar lavage (to isolate organism)
  • CT chest (carcinoma or possible empyema?)
  • Bronchoscopy (if suspect foreign body or carcinoma)

Differential diagnoses

  • Pulmonary embolus
  • Pleural effusion
  • Pneumothorax 
  • Pulmonary neoplasm   
  • Pulmonary haemorrhage (?part of Pulmonary-Renal Syndrome, eg Goodpasture's; v rare)                
  • Simple LRTI (normal CXR)
  • Lung abscess
  • (Unilateral) pulmonary oedema

Treatment

Some well patients with pneumonia can be managed as an outpatient 

Treatment

Drugs

  • CAP (community-acquired, non-severe)
    • PO AMOXICILLN 500 mg tds + PO ERYTHROMYCIN 500 mg qds (Penicillin Allergy: PO ERYTHROMYCIN 500 mg qds)
      Note: If atypical pathogen suspected, refer to respiratory physician for advice
  • CAP (community-acquired, severe)
    • IV CO-AMOXICLAV 1.2g  tds + IV ERYTHROMYCIN 500 mg qds (Penicillin Allergy: IV ERTAPENEM 1g od + IV ERYTHROMYCIN 500 mg qds)
      Notes: change to oral after 48hrs if patient improving; some infections (eg Legionella) may require 10-14 days treatment; IV macrolides require central line, or large bore IV cannula
  • (Community-Acquired) Aspiration Pneumonia
    • IV CO-AMOXICLAV 1.2 g tds (Penicillin Allergy: IV ERTAPENEM 1 g od)
  • Hospital-Acquired Pneumonia (HAP)/No antibiotics since admission
    • IV CO-AMOXICLAV 1.2 g tds + IV GENTAMICIN 5 mg/kg od (Penicilin Allergy: IV MEROPENEM 1 g tds + IV GENTAMICIN 5 mg/kg od)
  • HAP/Received antibiotics since admission
    • IV TAZOCIN 4.5 g tds + IV GENTAMICIN 5 mg/kg od (Penicillin Allergy: IV MEROPENEM 1 g tds + IV GENTAMICIN 5 mg/kg od)
      Note: atypical, opportunistic or neutropenic patients may require different antibiotics (DW microbiology)

Procedures

  • PO PARACETAMOL 1 g qds, if pain
  • IV line (and fluids; almost always dry)
  • OXYGEN, if hypoxic; % according to needs (± COPD) initially, via Venturi Mask; to keep SpO2 95-97%
    [Ref]

Key management decisions

  • Ventilate/not
  • ITU/not

Stop/reduce

  • Immunosuppression (DW prescriber)

Treatment (second line)

Drugs

  • For septic shock (inotropes etc)
  • Non-standard antibiotics (if suspect opportunistic organism); eg cotrimoxazole (for PCP), TB Rx, antiviral and antifungal agents (after DW microbiology)

Procedures

  • Urinary catheter, CVP line, arterial line

Prescribing issues

  • AB therapy should be orientated to the type of pneumonia

Admit?

  • Usually; but, if well, CURB-65 0-1, and good home support, can be handled as OP - with appropriate follow-up

Bed plan

  • Medical admission ward
  • ± Respiratory
  • ± ITU

Referrals

Medical

  • Senior if CURB ≥ 2
  • ± ITU, if CURB 65 ≥ 3
  • ± Respiratory (if diagnosis unclear, or suspect underlying cause)
  • ± MB/Infectious diseases (if diagnosis unclear and/or unusual organisms)

Other

  • Respiratory nurse (especially if underlying COPD)

The Rest

Use the CURB-65 score, its very simple and helpful as a management guide

Maxim

  • 'Who ever died of pneumonia?'

Complications

  • Parapneumonic effusion, empyema, lung abscess or systemic dissemination

Follow-up

  • GP
  • Respiratory, if disease/organism unusual, or suspect underlying carcimona
    Note: recheck CXR in > 6 wks, if suspect underlying Ca (radiological signs should have cleared by then)

Prognosis

  • Mortality is 10% in CAP (community-acquired pneumonia); 20% in healthcare–associated pneumonia (HCAP), and hospital-acquired pneumonia (HAP); and 30% in ventilator-associated pneumonia (VAP)
  • ie, Death more common in elderly, from nursing home, septicaemic, ITU

Score

  • CURB 65 (acronym for each of risk factors measured, each scoring one point, maximum score = 5); it was developed to combat the problem of not taking this disease seriously, especially in >75 yrs, where mortality can be much higher than 10%; it may require aggressive therapy
    1.    confusion (defined as an AMT of 8 or less)
    2.    urea > 7 mmol/l
    3.    respiratory rate > 30
    4.    blood pressure <90 systolic or <60 diastolic
    5.    age 65 or older

Risk stratification (who can be managed as outpatient)

  • If well, CURB-65 0-1, and good home support, can be handled as OP - with appropriate follow-up. There are more complicated systems: [Ref]

2° Prevention + Health Promotion

  • Stop smoking/alcohol
  • Reduce/stop immunosuppresion (after DW prescriber)
  • Pneumococcal vaccine (at risk groups eg >65; DM, CRF, CCF, CLF, COPD, immunosuppressed)

Don't forget

  • Recheck CXR in > 6 wks, if suspect underlying Ca    
  • If not getting better at 48h, DW microbiology, and ?change antibiotics
  • TB

Red flags

  • CURB 65 ≥ 2, ask for senior review; ≥ 3 ask for ITU opinion

References

international guidelines Canada/CIDS-CTS: Canadian Guidelines for the Initial Management of Community-Acquired Pneumonia: An Evidence-Based Update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. Mandel LA et al. Clinical Infectious Diseases; 31: 3

US/IDS-ATS: Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults. Mandell LA. Clin Inf Dis; 44: S27–72, 2007

national guidelines UK/BTS guidelines for the management of community aquired pneumonia in adults, 2009 update

UK/BSAC: Guidelines for the management of hospital-acquired pneumonia in the UK: Report of the Working Party on Hospital-Acquired Pneumonia of the British Society for Antimicrobial Chemotherapy. Masterton RG. Journal of Antimicrobial Chemotherapy; 62: 5–3

reviews Community-acquired pneumonia. File TM Jr. Lancet; 362: 1991–2001, 2003 (pdf)

Management of community-acquired pneumonia in adults. Feldman C et al. S Afr Med J; 97(12), 2007 (pdf)